For decades, the landscape of clinical research was dominated by fixed, traditional trial designs. In these legacy studies, the primary objective was often maintaining a strict, unchanging protocol from inception to conclusion. But the landscape of modern medicine has been forced to evolve dramatically, especially in fields like oncology. Today, the focus is shifting toward adaptive trial designs, which allow researchers to learn and adapt in real time to reach definitive outcomes faster.
Driven by urgent medical needs and increasingly complex drug technologies, this shift is more than just a methodological preference and has become a moral and operational imperative to reach the patients who are suffering the most. Current treatments in oncology often have severe side effects for patients; too often doctors are forced to choose a toxic cocktail of drugs in order to give their patients the best chance of survival and remission. While they’re the best that we have, these treatment regimens can leave people scarred in other ways beyond cancer. In my opinion, we must do better. We need treatments that can both save patient lives and not give them severe side effects or cause them to have permanent harm.
Over my 33 years of biopharmaceutical leadership, spanning roles from manufacturing and regulatory affairs to serving as CEO of multiple public biotech companies, I have witnessed the immense friction of rigid trial designs. To accelerate the delivery of life-saving therapies, more companies must adopt adaptive frameworks.
The Urgency of Now
A Phase 3 clinical trial is often the most expensive and risky step in drug development. Traditionally, companies have used a fixed or rigid trial design, where every parameter like sample size, dosage, patient population, endpoints, etc., are locked in before the first patient is even enrolled. But if the initial assumptions based on previous data were slightly off, the trial could fail entirely before it even gets off the ground. Nobody wins in this scenario, especially not the patients.
An adaptive trial design changes this dynamic. It allows researchers to prospectively plan mid-course adjustments based on accumulating trial information, without compromising the scientific validity, blinding or integrity of the study.
The fundamental limitation of traditional Phase 3 designs is their inability to pivot. In oncology, we are combating diseases that are inherently multifactorial and incredibly complex. Treatments continuously evolve as new agents such as biologics, cell therapies, and drug delivery technologies are discovered and introduced to an already intricate set of therapeutic options.
The fact of the matter is cancer patients do not have the luxury of time. Adaptive studies provide a highly effective mechanism to improve patient outcomes sooner. By leveraging a framework that learns as it gathers information, sponsors can navigate the complexities of urgent medical needs with agility.
Mechanisms of Momentum
Adaptive trial designs encompass several strategic methodologies that allow sponsors to course correct based on feedback about on clinical operational activities. The industry needs to utilize these tools more broadly to successfully pivot from flawed methodology or improper targets.
For instance, if a drug is clearly failing, sponsors can employ early stopping for futility or efficacy to halt the trial, saving valuable time and protecting patients from unnecessary exposure to inferior therapies. Additionally, through sample size re-estimation, trials can be expanded mid-stream if initial estimates regarding patient population needs fall short, ensuring the study retains the statistical power required to reach a sound conclusion. Furthermore, when clinical programs are testing multiple doses or drugs, a drop-the-loser or pick-the-winner approach can systematically eliminate underperforming arms, allowing resources to be rapidly shifted to the most promising candidates.
Finally, many are now also utilizing a seamless Phase 2/3 design, where researchers can combine two distinct phases into a single study. This enables them to identify the best dose in the first part and immediately transition to testing that dose for final approval, drastically cutting down administrative and operational downtime.
Operational Realities from the Helm
While the theoretical benefits of adaptive designs are clear, executing them requires rigorous operational discipline. An adaptive study must always balance operational efficiency with strict interpretability and regulatory rigor.
As a CEO navigating late-stage clinical development, I know firsthand that drafting an adaptive protocol requires foresight. Sponsors must anticipate where changes may be needed from the very beginning.
This includes complex logistical considerations like stratification and randomization. In randomized controlled studies, the target population must remain consistent across all evaluated cohorts. Selecting strong prognostic factors such as biomarkers, disease severity, and age is critical to ensure balanced treatment groups, as proper stratification and randomization programs are essential for reducing bias and producing high-quality data.
Beyond patient allocation, sponsors must carefully navigate blinding decisions by weighing the benefits of open label versus blinded studies. While blinding eliminates bias, it can be notoriously challenging to implement when dealing with various routes of drug administration across study arms. If a study utilizes a definitive endpoint, such as overall survival versus progression-free survival, an open-label approach becomes highly acceptable.
Lastly, the success of an adaptive trial hinges on exceptional site and data management. These trials demand experienced investigative sites capable of handling novel investigational products and supporting fluid trial requirements. Because adaptations rely heavily on real-time insights, sponsors must ensure that monitoring is frequent and data queries are addressed immediately.
Aligning with Regulators
Adaptability does not mean a lack of structure, and it is not a magic bullet that’s going to mean every Phase 3 will be successful. Regulatory agencies, including the FDA, expect adaptive Phase 3 trials to be safe for participants, consistently conducted across all sites, and free of bias. Dosing in various cohorts must also remain rigorous and independent of location.
To achieve this, early alignment with health authorities on the study design is absolutely crucial for registration studies. This means efficient meetings with the FDA, EMA, and others. It will require intense upfront statistical modeling and simulations to satisfy regulatory bodies that mid-course changes won’t introduce bias or inflate false positives. Sponsors will have to clearly elucidate the core design considerations including adaptivity, control selection, and outcome expectations to justify the proposed combinations and demonstrate scientific synergy.
This, of course, results in a slower build-up process to Phase 3, and a lot of extra work for the clinical team, but the result is a trial that is much more resilient to the difficulties that will arise during the course of your trial. The more resilient we can make our clinical programs, the better outcomes we will be able to determine for our patients.
A Call for Industry-Wide Adoption
Adaptive trial design is currently reshaping the clinical research landscape, delivering greater affordability, enhanced operational efficiency, and improved efficacy outcomes across the drug development life cycle leading to shorter approval times. Preplanned modifications based on interim data inherently accelerate timelines, increasing the probability that promising therapies will reach the patients who desperately need them.
As the costs of drug development rise and regulatory expectations shift, adaptive methodologies offer a highly practical solution to maintaining scientific integrity while boosting overall success rates. Moving forward, particularly as we look toward broader integration of real-time data analytics and AI-driven decision tools, the biopharma industry will see adaptive trials as a best practice and start adopting them as the foundational design motif.
Author Bio
Lew Bender, Founder and CEO of Intensity Therapeutics
Lew Bender is Founder and CEO of Intensity Therapeutics. He has more than 33 years of biopharmaceutical leadership experience and has helped take products leveraging novel drug delivery techniques from discovery through product approval. Lew founded Intensity Therapeutics and its foundational science. Including Intensity, he has been CEO of two other public biotech companies, a personalized medicine company (IG) and a drug delivery company (Emisphere). During his career, Lew held numerous positions in addition to the CEO role, including head of business development, manufacturing, process development, regulatory affairs, and quality control.
